Genetic markers may help predict response to TNF inhibitor therapy in rheumatoid arthritis, potentially leading to more ...

TNF inhibitors can induce remission and prevent both clinical and radiological disease progression in rheumatoid arthritis with significant improvement in patients' symptoms, function and quality ...

A Janus kinase (JAK) inhibitor outperformed tumor necrosis factor (TNF) blockers for substantially reducing rheumatoid arthritis (RA) symptoms in patients for whom conventional anti-rheumatic ...

can a TNF inhibitor be safely withdrawn once a state ... activity or remission was far out of reach for patients with RA; fortunately, this has changed in the recent past, given the appearance ...

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials ...

ORLANDO -- Major cardiovascular event risk in patients with inflammatory bowel disease (IBD) was no greater with Janus kinase ...

Targeted drugs for rheumatoid arthritis (RA ... on a 100-point scale compared with those using tumor necrosis factor (TNF) ...

The first type of biologic approved for use in treating RA was designed to target the protein called TNF. These drugs are called anti-TNF biologics, and they block specific steps in the ...

Early treatment escalation to biologic or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) following methotrexate (MTX) failure in new-onset rheumatoid arthritis (RA) does not ...

Rheumatoid arthritis (RA) has been a major growth driver for the pharmaceutical industry over the last 15 years, led by AbbVie’s blockbuster anti-TNF inhibitor treatment Humira (adalimumab).